Männedorf, Switzerland – Tecan and DYNEX Technologies have announced a partnership to broaden the availability of quality ELISA products in the US. Customers will now have direct access to Tecan’s ELISA-related kits and comprehensive portfolio of reagents alongside DYNEX’s fully automated ELISA workstations. This exciting collaboration between two market leaders will vastly expand customer reach across the US, providing access to a wide range of innovative laboratory solutions.
DYNEX Technologies, a US-based designer and manufacturer of fully automated ELISA microplate workstations, brings decades of US market experience – along with established customer and install bases – to the partnership, expanding market reach and streamlining purchasing options. Tecan complements this with its comprehensive portfolio of ELISA-related kits and reagents, including specialty immunoassays for endocrinology, immunology, autoimmunity and infectious diseases. Tecan is also a market leader in saliva diagnostics, bringing a broad portfolio of ELISA and luminescence-based tests to the table.
Dr Dagmar Kasper, Managing Director of Tecan’s reagent business, said: “We are excited to partner with DYNEX Technologies in the US to support Tecan’s purpose of scaling healthcare innovation globally. We look forward to working together to broaden the availability of our comprehensive portfolio of products and services.”
DYNEX Chief Executive Officer, Lisa Miller, expressed her confidence in this significant and strategic new business alliance between DYNEX and Tecan: “We are excited to partner with Tecan, because quality is the cornerstone of both businesses. Together, we can enhance the US customer experience and deliver consolidated purchasing options through DYNEX. Our partnership with Tecan provides us another opportunity to deliver a seamless and comprehensive product experience to our customers.”
To learn more about this partnership visit www.dynexandtecan.com
About DYNEX Technologies
DYNEX Technologies Inc. (www.dynex.com) is a pioneer in the design and manufacturing of fully automated ELISA and Chemiluminescence microplate technology. For over 70 years, DYNEX has earned a global reputation for delivering diagnostic and immunoassay instrumentation that maximize reagent performance and optimize laboratory productivity, with complete assay accuracy, on which clinicians depend. Quality is the cornerstone of the DYNEX brand. The company’s U.S. manufactured, ISO certified, instruments offer scalable processing solutions to achieve optimal workflow proficiency for laboratories of all sizes and specialties. DYNEX Technologies supports clinical diagnostic communities in over 120 countries worldwide and is headquartered in Chantilly, Virginia.
Tecan (www.tecan.com) improves people’s lives and health by empowering customers to scale healthcare innovation globally from life science to the clinic. Tecan is a pioneer and global leader in laboratory automation. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments, components and medical devices that are then distributed by partner companies. Founded in Switzerland in 1980, the company has more than 3,000 employees, with manufacturing, research and development sites in Europe, North America and Asia, and maintains a sales and service network in over 70 countries. In 2022, Tecan generated sales of CHF 1,144 million (USD 1,192 million; EUR 1,144 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).
For further information:
Contact: Chalice McGee
DYNEX Media Liaison
Contact: Magali Wolff
Tecan Media Liaison
Editorial contact for further information or follow-up
Becca Nordstrom at kdm communications limited, St Neots, UK
email [email protected]